• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO BCT TRIMA ACCEL; TRIMA ACCEL RBC PLT/PLASMA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO BCT TRIMA ACCEL; TRIMA ACCEL RBC PLT/PLASMA Back to Search Results
Catalog Number 80400
Medical Device Problem Codes No Apparent Adverse Event (3189); Insufficient Device Problem Information (3190)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 08/10/2023
Type of Reportable Event Malfunction
Event or Problem Description
Per journal article "posttransfusion sepsis attributable to bacterial contamination in platelet collection set manufacturing facility, united states" by ian kracalik, et all.During (b)(6) 2022, we reviewed transfusion-transmitted sepsis cases in the united states attributable to polymicrobial contaminated apheresis platelet components, including acinetobacter calcoaceticus baumannii complex or staphylococcus saprophyticus isolated from patients and components.Transfused platelet components underwent bacterial risk control strategies (primary culture, pathogen reduction or primary culture, and secondary rapid test) before transfusion.Environmental samples were collected from a platelet collection set manufacturing facility.Seven sepsis cases from 6 platelet donations from 6 different donors were identified in patients from 6 states; 3 patients died.Cultures identified acinetobacter calcoaceticus baumannii complex in 6 patients and 6 transfused platelets, s.Saprophyticus in 4 patients and 4 transfused platelets.Whole-genome sequencing showed environmental isolates from the manufacturer were closely related genetically to patient and platelet isolates, indicating the manufacturer was the most probable source of recurrent polymicrobial contamination.Clinicians should maintain awareness of possible transfusion-transmitted sepsis even when using bacterial risk control strategies.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.Patient information is unknown at this time.The collection set is not available for return because it was discarded by the customer.
 
Additional Manufacturer Narrative
Lot number and expiry information are not available at this time.Investigation is in process, a follow-up report will be provided.
 
Additional Manufacturer Narrative
This report is being filed to provide additional information in h.6, h.10 and h.11.Lot number and expiry information are not available at this time.It has been determined that the event submitted on this report is a duplicate of the event submitted on report 1722028-2024-00088.No further reporting will be provided as this does not represent a reportable event.
 
Event or Problem Description
Per journal article "posttransfusion sepsis attributable to bacterial contamination in platelet collection set manufacturing facility, united states" by ian kracalik, et all.During may 2018.December 2022, we reviewed transfusion-transmitted sepsis cases in the united states attributable to polymicrobial contaminated apheresis platelet components, including acinetobacter calcoaceticus baumannii complex or staphylococcus saprophyticus isolated from patients and components.Transfused platelet components underwent bacterial risk control strategies (primary culture, pathogen reduction or primary culture, and secondary rapid test) before transfusion.Environmental samples were collected from a platelet collection set manufacturing facility.Seven sepsis cases from 6 platelet donations from 6 different donors were identified in patients from 6 states; 3 patients died.Cultures identified acinetobacter calcoaceticus baumannii complex in 6 patients and 6 transfused platelets, s.Saprophyticus in 4 patients and 4 transfused platelets.Whole-genome sequencing showed environmental isolates from the manufacturer were closely related genetically to patient and platelet isolates, indicating the manufacturer was the most probable source of recurrent polymicrobial contamination.Clinicians should maintain awareness of possible transfusion-transmitted sepsis even when using bacterial risk control strategies.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.Patient information is unknown at this time.The collection set is not available for return because it was discarded by the customer.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRIMA ACCEL
Common Device Name
TRIMA ACCEL RBC PLT/PLASMA
Manufacturer (Section D)
TERUMO BCT
lakewood CO 80215
Manufacturer (Section G)
TERUMO BCT
10810 w. collins ave
lakewood CO 80215
Manufacturer Contact
scot hilden
10810 w. collins ave
lakewood, CO 80215
MDR Report Key17671711
Report Number1722028-2023-00295
Device Sequence Number6032659
Product Code GKT
UDI-Device Identifier05020583804005
UDI-Public05020583804005
Combination Product (Y/N)N
Initial Reporter StateGA
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Literature,Health Professional
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 09/01/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Catalogue Number80400
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 08/10/2023
Supplement Date Received by Manufacturer06/26/2024
Initial Report FDA Received Date09/01/2023
Supplement Report FDA Received Date06/27/2024
Was Device Evaluated by Manufacturer? (Y/N) No
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient SexUnknown
-
-